Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Amgen Inc

AMGN
Current price
294.79 USD -2.09 USD (-0.70%)
Last closed 307.81 USD
ISIN US0311621009
Sector Healthcare
Industry Drug Manufacturers - General
Exchange NASDAQ
Capitalization 141 575 438 336 USD
Yield for 12 month +0.12 %
1Y
3Y
5Y
10Y
15Y
AMGN
21.11.2021 - 28.11.2021

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California. Address: One Amgen Center Drive, Thousand Oaks, CA, United States, 91320-1799

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

322.43 USD

P/E ratio

33.68

Dividend Yield

3.05 %

Current Year

+28 190 000 000 USD

Last Year

+26 323 000 000 USD

Current Quarter

+8 503 000 000 USD

Last Quarter

+8 333 000 000 USD

Current Year

+19 739 000 000 USD

Last Year

+19 917 000 000 USD

Current Quarter

+5 193 000 000 USD

Last Quarter

+5 097 000 000 USD

Key Figures AMGN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA 12 247 000 064 USD
Operating Margin TTM 24.16 %
PE Ratio 33.68
Return On Assets TTM 4.60 %
PEG Ratio 1.87
Return On Equity TTM 55.72 %
Wall Street Target Price 322.43 USD
Revenue TTM 32 533 999 616 USD
Book Value 14.00 USD
Revenue Per Share TTM
Dividend Share 8.88 USD
Quarterly Revenue Growth YOY 23.20 %
Dividend Yield 3.05 %
Gross Profit TTM 19 917 000 000 USD
Earnings per share 7.82 USD
Diluted Eps TTM 7.82 USD
Most Recent Quarter III 2024
Quarterly Earnings Growth YOY 62.10 %
Profit Margin 13.00 %

Dividend Analytics AMGN

Champion - 10+ consecutive years of dividend increases

Max Ratio

>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.

7.67 %

5Y Dividend Growth

55.00 %

Consecutive Years

13 years

5Y Average Payout Ratio

25.00 %

Dividend History AMGN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate 9.52
Ex Dividend Date 14.02.2025
Forward Annual Dividend Yield 3.61 %
Last Split Factor 2:1
Payout Ratio 46.83 %
Last Split Date 22.11.1999
Dividend Date 07.03.2025

Stock Valuation AMGN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 33.68
Forward PE 12.66
Enterprise Value Revenue 5.93
Price Sales TTM 4.35
Enterprise Value EBITDA 14.31
Price Book MRQ 18.81

Financials AMGN

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators AMGN

For 52 weeks

253.30 USD 341.72 USD
50 Day MA 297.17 USD
Shares Short Prior Month 9 805 318
200 Day MA 305.01 USD
Short Ratio 2.89
Shares Short 11 137 469
Short Percent 2.07 %